REVELATION BIOSCIENCES INC
For the period ended Dec 31, 2023. Filed Mar 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 22, 2024
REVB$4.11+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year EndedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses: | ||
| Research and development | $4,145,902 | $5,377,400 |
| General and administrative | 4,510,762 | 5,487,111 |
| Total operating expenses | 8,656,664 | 10,864,511 |
| Loss from operations | (8,656,664) | (10,864,511) |
| Other income (expense): | ||
| Change in fair value of warrant liability | 8,328,937 | — |
| Other income (expense) | 207,473 | 34,962 |
| Total other income (expense), net | 8,536,410 | 34,962 |
| Net loss | $(120,254) | $(10,829,549) |
| Net loss per share, basic and diluted | $(0.53) | $(149.20) |
| Weighted-average shares used to compute net loss per share, basic and diluted | 228,641 | 72,585 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.